E138A in HIV-1 reverse transcriptase is more common in subtype C than B: Implications for rilpivirine use in resource-limited settings
Identifieur interne : 005611 ( Main/Exploration ); précédent : 005610; suivant : 005612E138A in HIV-1 reverse transcriptase is more common in subtype C than B: Implications for rilpivirine use in resource-limited settings
Auteurs : Nicolas Sluis-Cremer [États-Unis] ; Michael R. Jordan [États-Unis] ; Kelly Huber [États-Unis] ; Carole L. Wallis [Afrique du Sud] ; Silvia Bertagnolio [Suisse] ; John W. Mellors [États-Unis] ; Neil T. Parkin [États-Unis] ; P. Richard Harrigan [Canada]Source :
- Antiviral research [ 0166-3542 ] ; 2014.
Descripteurs français
- KwdFr :
- Agents antiVIH (pharmacologie), Humains, Infections à VIH (traitement médicamenteux), Infections à VIH (virologie), Mutation faux-sens, Nitriles (pharmacologie), Pyrimidines (pharmacologie), Rilpivirine, Résistance virale aux médicaments, Substitution d'acide aminé, Transcriptase inverse du VIH (génétique), Transcriptase inverse du VIH (métabolisme), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (enzymologie), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (génétique).
- MESH :
- enzymologie : VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- génétique : Transcriptase inverse du VIH, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- métabolisme : Transcriptase inverse du VIH.
- pharmacologie : Agents antiVIH, Nitriles, Pyrimidines.
- traitement médicamenteux : Infections à VIH.
- virologie : Infections à VIH.
- Pascal (Inist)
- Humains, Mutation faux-sens, Rilpivirine, Résistance virale aux médicaments, Substitution d'acide aminé, VIH-1 (Virus de l'Immunodéficience Humaine de type 1), Virus HIV1, SIDA, RNA-directed DNA polymerase, Rilpivirine, Ressource, Inhibiteur reverse transcriptase, Composé non nucléoside, Résistance, Antiviral, Reverse transcriptase, Soustype C.
English descriptors
- KwdEn :
- AIDS, Amino Acid Substitution, Anti-HIV Agents (pharmacology), Antiviral, Drug Resistance, Viral, HIV Infections (drug therapy), HIV Infections (virology), HIV Reverse Transcriptase (genetics), HIV Reverse Transcriptase (metabolism), HIV-1 (classification), HIV-1 (enzymology), HIV-1 (genetics), HIV-1 virus, Humans, Mutation, Missense, Nitriles (pharmacology), Non nucleoside compound, Pyrimidines (pharmacology), RNA-directed DNA polymerase, Resistance, Resource, Reverse transcriptase inhibitor, Rilpivirine.
- MESH :
- chemical , genetics : HIV Reverse Transcriptase.
- chemical , metabolism : HIV Reverse Transcriptase.
- chemical , pharmacology : Anti-HIV Agents, Nitriles, Pyrimidines.
- classification : HIV-1.
- drug therapy : HIV Infections.
- enzymology : HIV-1.
- genetics : HIV-1.
- virology : HIV Infections.
- Amino Acid Substitution, Drug Resistance, Viral, Humans, Mutation, Missense, Rilpivirine.
Abstract
The nonnucleoside reverse transcriptase (RT) inhibitor rilpivirine (RPV) has been co-formulated with emtricitabine and tenofovir disoproxil fumarate for initial therapy of HIV-1-infected individuals. RPV, formulated as a long-acting nanosuspension, will also be assessed for its ability to prevent HIV-1 infection in resource limited settings. In this study, we determined whether any pre-existing genetic differences occurred among different HIV-1 subtypes at residues in RT associated with decreased virologic response to RPV. We found that the E138A substitution occurs more frequently in subtype C (range: 5.9-7.5%) than B (range: 0-2.3%) sequences from both treatment-naïve and -experienced individuals (p < 0.01) in 4 independent genotype databases. In one of the databases (Stanford University), E138K and E138Q were also more common in RTI-experienced subtype C sequences (1.0% and 1.1%, respectively) than in subtype B sequences (0.3% and 0.6%, respectively). E138A/K/Q in subtype C decreased RPV susceptibility 2.9-, 5.8-, and 5.4-fold, respectively. Taken together, these data suggest that E138A could impact treatment or prevention strategies that include RPV in geographic areas where subtype C infection is prevalent.
Url:
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000923
- to stream PascalFrancis, to step Curation: 003D07
- to stream PascalFrancis, to step Checkpoint: 000998
- to stream Main, to step Merge: 005921
- to stream Pmc, to step Corpus: 001488
- to stream Pmc, to step Curation: 001463
- to stream Pmc, to step Checkpoint: 001541
- to stream PubMed, to step Corpus: 002772
- to stream PubMed, to step Curation: 002762
- to stream PubMed, to step Checkpoint: 002762
- to stream Ncbi, to step Merge: 001C03
- to stream Ncbi, to step Curation: 001C03
- to stream Ncbi, to step Checkpoint: 001C03
- to stream Main, to step Merge: 003392
- to stream Main, to step Curation: 005611
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">E138A in HIV-1 reverse transcriptase is more common in subtype C than B: Implications for rilpivirine use in resource-limited settings</title><author><name sortKey="Sluis Cremer, Nicolas" sort="Sluis Cremer, Nicolas" uniqKey="Sluis Cremer N" first="Nicolas" last="Sluis-Cremer">Nicolas Sluis-Cremer</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Pittsburgh School of Medicine, Department of Medicine, Division of Infectious Diseases</s1><s2>Pittsburgh, PA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Pittsburgh, PA</wicri:noRegion></affiliation></author><author><name sortKey="Jordan, Michael R" sort="Jordan, Michael R" uniqKey="Jordan M" first="Michael R." last="Jordan">Michael R. Jordan</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Division of Geographic Medicine and Infectious Disease, Tufts Medical Center</s1><s2>Boston</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Boston</settlement><region type="state">Massachusetts</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Public Health and Community Medicine, Tufts University School of Medicine</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Boston, MA</wicri:noRegion></affiliation></author><author><name sortKey="Huber, Kelly" sort="Huber, Kelly" uniqKey="Huber K" first="Kelly" last="Huber">Kelly Huber</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Pittsburgh School of Medicine, Department of Medicine, Division of Infectious Diseases</s1><s2>Pittsburgh, PA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Pittsburgh, PA</wicri:noRegion></affiliation></author><author><name sortKey="Wallis, Carole L" sort="Wallis, Carole L" uniqKey="Wallis C" first="Carole L." last="Wallis">Carole L. Wallis</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Lancet Laboratories</s1><s2>Johannesburg</s2><s3>ZAF</s3><sZ>4 aut.</sZ></inist:fA14><country>Afrique du Sud</country><wicri:noRegion>Lancet Laboratories</wicri:noRegion></affiliation></author><author><name sortKey="Bertagnolio, Silvia" sort="Bertagnolio, Silvia" uniqKey="Bertagnolio S" first="Silvia" last="Bertagnolio">Silvia Bertagnolio</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>HIV Department, World Health Organization</s1><s2>Geneva</s2><s3>CHE</s3><sZ>5 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>Geneva</wicri:noRegion></affiliation></author><author><name sortKey="Mellors, John W" sort="Mellors, John W" uniqKey="Mellors J" first="John W." last="Mellors">John W. Mellors</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Pittsburgh School of Medicine, Department of Medicine, Division of Infectious Diseases</s1><s2>Pittsburgh, PA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Pittsburgh, PA</wicri:noRegion></affiliation></author><author><name sortKey="Parkin, Neil T" sort="Parkin, Neil T" uniqKey="Parkin N" first="Neil T." last="Parkin">Neil T. Parkin</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Data First Consulting</s1><s2>Belmont, CA</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Data First Consulting</wicri:noRegion></affiliation></author><author><name sortKey="Harrigan, P Richard" sort="Harrigan, P Richard" uniqKey="Harrigan P" first="P. Richard" last="Harrigan">P. Richard Harrigan</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>BC Centre for Excellence in HIV/AIDS</s1><s2>Vancouver</s2><s3>CAN</s3><sZ>8 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>BC Centre for Excellence in HIV/AIDS</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">14-0168537</idno><date when="2014">2014</date><idno type="stanalyst">PASCAL 14-0168537 INIST</idno><idno type="RBID">Pascal:14-0168537</idno><idno type="wicri:Area/PascalFrancis/Corpus">000923</idno><idno type="wicri:Area/PascalFrancis/Curation">003D07</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000998</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000998</idno><idno type="wicri:doubleKey">0166-3542:2014:Sluis Cremer N:e:a:in</idno><idno type="wicri:Area/Main/Merge">005921</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4089891</idno><idno type="RBID">PMC:4089891</idno><idno type="wicri:Area/Pmc/Corpus">001488</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001488</idno><idno type="wicri:Area/Pmc/Curation">001463</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001463</idno><idno type="wicri:Area/Pmc/Checkpoint">001541</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001541</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">002772</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002772</idno><idno type="wicri:Area/PubMed/Curation">002762</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002762</idno><idno type="wicri:Area/PubMed/Checkpoint">002762</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002762</idno><idno type="wicri:Area/Ncbi/Merge">001C03</idno><idno type="wicri:Area/Ncbi/Curation">001C03</idno><idno type="wicri:Area/Ncbi/Checkpoint">001C03</idno><idno type="wicri:doubleKey">0166-3542:2014:Sluis Cremer N:e:a:in</idno><idno type="wicri:Area/Main/Merge">003392</idno><idno type="wicri:Area/Main/Curation">005611</idno><idno type="wicri:Area/Main/Exploration">005611</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">E138A in HIV-1 reverse transcriptase is more common in subtype C than B: Implications for rilpivirine use in resource-limited settings</title><author><name sortKey="Sluis Cremer, Nicolas" sort="Sluis Cremer, Nicolas" uniqKey="Sluis Cremer N" first="Nicolas" last="Sluis-Cremer">Nicolas Sluis-Cremer</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Pittsburgh School of Medicine, Department of Medicine, Division of Infectious Diseases</s1><s2>Pittsburgh, PA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Pittsburgh, PA</wicri:noRegion></affiliation></author><author><name sortKey="Jordan, Michael R" sort="Jordan, Michael R" uniqKey="Jordan M" first="Michael R." last="Jordan">Michael R. Jordan</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Division of Geographic Medicine and Infectious Disease, Tufts Medical Center</s1><s2>Boston</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Boston</settlement><region type="state">Massachusetts</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Public Health and Community Medicine, Tufts University School of Medicine</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Boston, MA</wicri:noRegion></affiliation></author><author><name sortKey="Huber, Kelly" sort="Huber, Kelly" uniqKey="Huber K" first="Kelly" last="Huber">Kelly Huber</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Pittsburgh School of Medicine, Department of Medicine, Division of Infectious Diseases</s1><s2>Pittsburgh, PA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Pittsburgh, PA</wicri:noRegion></affiliation></author><author><name sortKey="Wallis, Carole L" sort="Wallis, Carole L" uniqKey="Wallis C" first="Carole L." last="Wallis">Carole L. Wallis</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Lancet Laboratories</s1><s2>Johannesburg</s2><s3>ZAF</s3><sZ>4 aut.</sZ></inist:fA14><country>Afrique du Sud</country><wicri:noRegion>Lancet Laboratories</wicri:noRegion></affiliation></author><author><name sortKey="Bertagnolio, Silvia" sort="Bertagnolio, Silvia" uniqKey="Bertagnolio S" first="Silvia" last="Bertagnolio">Silvia Bertagnolio</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>HIV Department, World Health Organization</s1><s2>Geneva</s2><s3>CHE</s3><sZ>5 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>Geneva</wicri:noRegion></affiliation></author><author><name sortKey="Mellors, John W" sort="Mellors, John W" uniqKey="Mellors J" first="John W." last="Mellors">John W. Mellors</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Pittsburgh School of Medicine, Department of Medicine, Division of Infectious Diseases</s1><s2>Pittsburgh, PA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Pittsburgh, PA</wicri:noRegion></affiliation></author><author><name sortKey="Parkin, Neil T" sort="Parkin, Neil T" uniqKey="Parkin N" first="Neil T." last="Parkin">Neil T. Parkin</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Data First Consulting</s1><s2>Belmont, CA</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Data First Consulting</wicri:noRegion></affiliation></author><author><name sortKey="Harrigan, P Richard" sort="Harrigan, P Richard" uniqKey="Harrigan P" first="P. Richard" last="Harrigan">P. Richard Harrigan</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>BC Centre for Excellence in HIV/AIDS</s1><s2>Vancouver</s2><s3>CAN</s3><sZ>8 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>BC Centre for Excellence in HIV/AIDS</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Antiviral research</title><title level="j" type="abbreviated">Antivir. res.</title><idno type="ISSN">0166-3542</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Antiviral research</title><title level="j" type="abbreviated">Antivir. res.</title><idno type="ISSN">0166-3542</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS</term><term>Amino Acid Substitution</term><term>Anti-HIV Agents (pharmacology)</term><term>Antiviral</term><term>Drug Resistance, Viral</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (virology)</term><term>HIV Reverse Transcriptase (genetics)</term><term>HIV Reverse Transcriptase (metabolism)</term><term>HIV-1 (classification)</term><term>HIV-1 (enzymology)</term><term>HIV-1 (genetics)</term><term>HIV-1 virus</term><term>Humans</term><term>Mutation, Missense</term><term>Nitriles (pharmacology)</term><term>Non nucleoside compound</term><term>Pyrimidines (pharmacology)</term><term>RNA-directed DNA polymerase</term><term>Resistance</term><term>Resource</term><term>Reverse transcriptase inhibitor</term><term>Rilpivirine</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Agents antiVIH (pharmacologie)</term><term>Humains</term><term>Infections à VIH (traitement médicamenteux)</term><term>Infections à VIH (virologie)</term><term>Mutation faux-sens</term><term>Nitriles (pharmacologie)</term><term>Pyrimidines (pharmacologie)</term><term>Rilpivirine</term><term>Résistance virale aux médicaments</term><term>Substitution d'acide aminé</term><term>Transcriptase inverse du VIH (génétique)</term><term>Transcriptase inverse du VIH (métabolisme)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) ()</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (enzymologie)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (génétique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>HIV Reverse Transcriptase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>HIV Reverse Transcriptase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-HIV Agents</term><term>Nitriles</term><term>Pyrimidines</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Transcriptase inverse du VIH</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Transcriptase inverse du VIH</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Agents antiVIH</term><term>Nitriles</term><term>Pyrimidines</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Amino Acid Substitution</term><term>Drug Resistance, Viral</term><term>Humans</term><term>Mutation, Missense</term><term>Rilpivirine</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Humains</term><term>Mutation faux-sens</term><term>Rilpivirine</term><term>Résistance virale aux médicaments</term><term>Substitution d'acide aminé</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term><term>Virus HIV1</term><term>SIDA</term><term>RNA-directed DNA polymerase</term><term>Rilpivirine</term><term>Ressource</term><term>Inhibiteur reverse transcriptase</term><term>Composé non nucléoside</term><term>Résistance</term><term>Antiviral</term><term>Reverse transcriptase</term><term>Soustype C</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The nonnucleoside reverse transcriptase (RT) inhibitor rilpivirine (RPV) has been co-formulated with emtricitabine and tenofovir disoproxil fumarate for initial therapy of HIV-1-infected individuals. RPV, formulated as a long-acting nanosuspension, will also be assessed for its ability to prevent HIV-1 infection in resource limited settings. In this study, we determined whether any pre-existing genetic differences occurred among different HIV-1 subtypes at residues in RT associated with decreased virologic response to RPV. We found that the E138A substitution occurs more frequently in subtype C (range: 5.9-7.5%) than B (range: 0-2.3%) sequences from both treatment-naïve and -experienced individuals (p < 0.01) in 4 independent genotype databases. In one of the databases (Stanford University), E138K and E138Q were also more common in RTI-experienced subtype C sequences (1.0% and 1.1%, respectively) than in subtype B sequences (0.3% and 0.6%, respectively). E138A/K/Q in subtype C decreased RPV susceptibility 2.9-, 5.8-, and 5.4-fold, respectively. Taken together, these data suggest that E138A could impact treatment or prevention strategies that include RPV in geographic areas where subtype C infection is prevalent.</div></front></TEI><affiliations><list><country><li>Afrique du Sud</li><li>Canada</li><li>Suisse</li><li>États-Unis</li></country><region><li>Massachusetts</li></region><settlement><li>Boston</li></settlement></list><tree><country name="États-Unis"><noRegion><name sortKey="Sluis Cremer, Nicolas" sort="Sluis Cremer, Nicolas" uniqKey="Sluis Cremer N" first="Nicolas" last="Sluis-Cremer">Nicolas Sluis-Cremer</name></noRegion><name sortKey="Huber, Kelly" sort="Huber, Kelly" uniqKey="Huber K" first="Kelly" last="Huber">Kelly Huber</name><name sortKey="Jordan, Michael R" sort="Jordan, Michael R" uniqKey="Jordan M" first="Michael R." last="Jordan">Michael R. Jordan</name><name sortKey="Jordan, Michael R" sort="Jordan, Michael R" uniqKey="Jordan M" first="Michael R." last="Jordan">Michael R. Jordan</name><name sortKey="Mellors, John W" sort="Mellors, John W" uniqKey="Mellors J" first="John W." last="Mellors">John W. Mellors</name><name sortKey="Parkin, Neil T" sort="Parkin, Neil T" uniqKey="Parkin N" first="Neil T." last="Parkin">Neil T. Parkin</name></country><country name="Afrique du Sud"><noRegion><name sortKey="Wallis, Carole L" sort="Wallis, Carole L" uniqKey="Wallis C" first="Carole L." last="Wallis">Carole L. Wallis</name></noRegion></country><country name="Suisse"><noRegion><name sortKey="Bertagnolio, Silvia" sort="Bertagnolio, Silvia" uniqKey="Bertagnolio S" first="Silvia" last="Bertagnolio">Silvia Bertagnolio</name></noRegion></country><country name="Canada"><noRegion><name sortKey="Harrigan, P Richard" sort="Harrigan, P Richard" uniqKey="Harrigan P" first="P. Richard" last="Harrigan">P. Richard Harrigan</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005611 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005611 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:14-0168537
|texte= E138A in HIV-1 reverse transcriptase is more common in subtype C than B: Implications for rilpivirine use in resource-limited settings
}}
| This area was generated with Dilib version V0.6.38. |  |